Core Insights - Teladoc (TDOC) shares increased by 14.4% to close at $7.89, driven by higher trading volume compared to typical sessions, contrasting with a 1.3% gain over the past four weeks [1] - Citron Research highlighted Teladoc's growth potential following a Goldman Sachs presentation, emphasizing the integration of BetterHelp in employer health plans and the recent acquisition of UpLift, which facilitates insurance billing [2] - Teladoc's competitive advantages include its comprehensive virtual care services, global reach, and data-driven innovations, offering a wide range of clinical services through a scalable and secure platform [3] Financial Performance - The company is expected to report a quarterly loss of $0.26 per share, reflecting a year-over-year increase of 7.1%, with anticipated revenues of $621.69 million, down 3.2% from the previous year [4] - The consensus EPS estimate for the quarter has been revised 3.4% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [5] Industry Context - Teladoc holds a Zacks Rank of 3 (Hold) within the Medical Services industry, alongside LifeMD, Inc. (LFMD), which experienced a 3.1% decline in the last trading session [6] - LifeMD's consensus EPS estimate remains unchanged at -$0.02, representing an 89.5% year-over-year change [7]

Company Performance - Teladoc's stock increased by 2.33% to $7.02, outperforming the S&P 500's daily gain of 0.94% [1] - Over the past month, Teladoc's stock has decreased by 8.78%, underperforming the Medical sector's gain of 4.95% and the S&P 500's gain of 1.67% [1] Upcoming Earnings - The upcoming earnings release is expected to show an EPS of -$0.24, which is a 14.29% increase compared to the same quarter last year [2] - Revenue is projected to be $621.69 million, reflecting a 3.23% decline from the equivalent quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at -$1.17 per share, representing an 80.07% increase from the prior year [3] - Revenue for the fiscal year is estimated at $2.52 billion, indicating a 2.12% decrease from the previous year [3] Analyst Estimates - Recent modifications to analyst estimates for Teladoc reflect short-term business trends, with positive revisions indicating analyst optimism [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Teladoc at 3 (Hold) [6] Industry Context - The Medical Services industry, part of the Medical sector, holds a Zacks Industry Rank of 67, placing it in the top 28% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Insights - Teladoc Health, Inc. is actively participating in the Goldman Sachs 46th Annual Global Healthcare Conference, indicating its commitment to engaging with investors and stakeholders in the healthcare sector [1]. Group 1: Company Overview - The CEO, Charles Divita, recently celebrated his one-year anniversary in the role, expressing excitement about the potential of virtual care to address healthcare challenges [4]. - Divita highlighted the positive aspects of the company, including its assets, talent level, and market position, which exceeded his expectations upon joining [4]. - The CEO also acknowledged the need for changes and the identification of opportunities and challenges that the company must address moving forward [4].

Financial Data and Key Metrics Changes - The company has seen a significant increase in membership, with over 100 million members now having access to its services, reflecting a 12% year-over-year growth in members in Q1 [20][23] - The transition from subscription-based models to utilization-based models has created a headwind for top-line growth, although underlying utilization and visits are growing [48][50] Business Line Data and Key Metrics Changes - The integrated care business has over 1 million people enrolled in chronic condition management programs, with a focus on enhancing offerings to drive more value for clients [10][14] - BetterHelp, the direct-to-consumer virtual therapy business, has a significant drop-off rate, with over 80% of users not converting to active users due to high out-of-pocket costs [35][37] Market Data and Key Metrics Changes - The international market represents about 15% of the revenues of integrated care, with expectations to grow upwards of 50% over the next few years [16] - Utilization levels in the U.S. are still in the mid to high single digits, indicating substantial room for growth in engagement and usage [29] Company Strategy and Development Direction - The company is focused on four strategic areas: integrated care, international expansion, operational excellence, and enhancing mental health services [9][19] - There is a strong emphasis on leveraging technology and data to improve engagement and drive better health outcomes, particularly in chronic care and mental health [12][60] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges posed by the shift from subscription to utilization models but remains optimistic about the growth potential in both domestic and international markets [48][50] - The company is committed to creating efficiencies while also investing in technology and capabilities to enhance service delivery [74][75] Other Important Information - The company has made strategic acquisitions, such as Catapult and Uplift, to enhance its capabilities in insurance coverage and chronic care management [61][62] - Adjusted EBITDA margins have remained flat year-over-year, with ongoing efforts to streamline costs and improve productivity [70][71] Q&A Session Summary Question: How does the company plan to grow revenue per integrated care member? - Management indicated that they are focused on a "land and expand" strategy, starting with core telehealth services and expanding into additional products and services [23][24] Question: What is the current mix between subscription and visit-based models? - The majority of the business has shifted to visit-based models post-pandemic, although the exact mix has not been publicly shared [50][51] Question: How does the company plan to maintain its leadership position in chronic disease management? - Management emphasized the importance of innovation and leveraging their extensive data and clinical capabilities to provide greater value than competitors [58][59]

Company Overview - Teladoc's stock closed at $7.40, reflecting a +1.79% change from the previous day, outperforming the S&P 500's daily gain of 0.09% [1] - Over the past month, Teladoc's stock has increased by 2.25%, slightly above the Medical sector's gain of 2.17%, but below the S&P 500's gain of 7.21% [1] Earnings Forecast - The upcoming earnings release is anticipated, with an expected EPS of -$0.23, indicating a 17.86% growth compared to the same quarter last year [2] - Revenue is forecasted to be $621.92 million, representing a 3.19% decline from the corresponding quarter of the previous year [2] Full Year Projections - For the full year, earnings are projected at -$1.17 per share and revenue at $2.51 billion, showing changes of +80.07% and -2.15% respectively from the previous year [3] Analyst Forecast Revisions - Recent revisions to analyst forecasts for Teladoc are important, as they reflect changes in short-term business dynamics [4] - Positive revisions indicate analysts' confidence in the company's performance and profit potential [4] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a history of outperforming, with 1 stocks averaging a +25% annual gain since 1988 [6] - Over the last 30 days, the Zacks Consensus EPS estimate for Teladoc has increased by 8.56%, and the company currently holds a Zacks Rank of 3 (Hold) [6] Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 68, placing it in the top 28% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

A month has gone by since the last earnings report for Teladoc (TDOC) . Shares have lost about 0.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Teladoc due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, fresh ...

Financial Data and Key Metrics Changes - The meeting confirmed that a majority of the voting power of Teladoc Health's outstanding capital stock was present, indicating strong shareholder engagement [4][11] - Proposals regarding the election of directors and executive compensation were approved, reflecting shareholder confidence in management [11] Business Line Data and Key Metrics Changes - Specific financial data and performance metrics for individual business lines were not disclosed during the meeting [10] Market Data and Key Metrics Changes - No specific market data or key metrics were discussed in the meeting [10] Company Strategy and Development Direction and Industry Competition - The meeting focused on the election of directors and approval of executive compensation, suggesting a stable governance structure [11] - The approval of the incentive award plan indicates a commitment to aligning executive performance with shareholder interests [8] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [10] Other Important Information - The meeting was conducted virtually, allowing stockholders to participate and vote online [5][9] - The results of the votes will be reported in a Form 8-K within four business days, ensuring transparency [11] Q&A Session Summary - No questions were raised during the Q&A session, indicating either satisfaction with the proposals or a lack of immediate concerns from shareholders [10]

Core Viewpoint - JPMorgan analyst Lisa C. Gill maintains a Neutral rating on Teladoc Health, Inc with a reduced price target of $9, down from $11 [1] Financial Performance - Teladoc reported first-quarter revenue of $629.4 million, a decrease of 3%, but exceeded the consensus estimate of $619.29 million [1] - The company incurred a first-quarter loss of 53 cents per share, which was worse than the analyst estimate of a loss of 34 cents per share [1] Future Revenue Guidance - For the second quarter, Teladoc expects revenue between $614 million and $633 million, and for the full year, revenue is projected to be between $2.47 billion and $2.58 billion [2] - Analysts are forecasting full-year revenue of $2.52 billion [2] Earnings Outlook - Teladoc has lowered its full-year earnings outlook, now anticipating a 2025 loss of $0.90 to $1.40 per share, down from a previous guidance of a loss of $0.50 to $1.10 per share [3] - Analysts forecast a loss of 93 cents per share for 2025 [3] Revenue and EBITDA Estimates - Following the first-quarter earnings, Gill adjusted her fiscal 2025 revenue estimate to $2.516 billion from $2.520 billion, and her adjusted EBITDA estimate to $282 million, down from $294 million [3] - For fiscal 2026, Gill lowered her revenue estimate to $2.547 billion from $2.560 billion and adjusted EBITDA estimate to $304 million from $314 million [4] Valuation and Market Position - Gill established a December 2025 price target of $9 based on an EV/adjusted EBITDA multiple of approximately 6.5 times her 2026 adjusted EBITDA estimate, which is a significant discount to Teladoc's pre-pandemic historical average multiple [4] - The company faces challenges and uncertainties in the DTC behavioral health business and a volatile macroeconomic environment [5] Growth Potential - Despite current challenges, there is a sizable Total Addressable Market (TAM) with significant growth potential due to continued virtual care adoption, a leading competitive position, and expansion opportunities [6] - The company has an attractive margin profile and a strong balance sheet, being EBITDA and cash flow positive [6] Stock Performance - Teladoc shares were up 2.4% at $7.43 as of the last check on Friday [6]

Group 1: Investment Opportunities - Equity markets present bargains with stocks that have underperformed but may rebound as conditions improve [1] - Moderna is highlighted as a beaten-down stock with promising prospects due to its advancements in mRNA technology and a strong pipeline of potential products [2][4] - Moderna's revenue guidance is projected at $2 billion, primarily from its COVID vaccine efforts, and the company plans to cut operating expenses by $1.4 billion to $1.7 billion by 2027 [8][9] Group 2: Company-Specific Analysis - Moderna - Moderna's mRNA-4157, a personalized cancer vaccine, has shown strong results in phase 2 studies and is currently in phase 3 trials [6] - The company is also developing a standalone influenza vaccine and a combined COVID/flu shot, both nearing approval [7] - Despite a decline in stock performance over the past three years, Moderna's potential for growth remains strong due to its innovative pipeline and cost-cutting measures [9] Group 3: Investment Risks - Teladoc Health, a telemedicine company, has seen a slowdown in revenue growth and remains unprofitable despite high gross margins [10] - In the first quarter, Teladoc's revenue decreased by 3% year over year to $629.4 million, with a net loss per share of $0.53 [11] - The company faces significant challenges, including a competitive landscape and declining membership in its therapy service, BetterHelp [13][14]

Core Viewpoint - Teladoc Health Inc. reported better-than-expected first-quarter 2025 results, but the outlook for 2025 has disappointed investors, leading to a 4.6% decline in shares since the earnings report [1] Financial Performance - The company incurred an adjusted loss of 19 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 33 cents and improved from a loss of 49 cents in the same quarter last year [2] - Operating revenues were $629.4 million, down from $646.1 million year-over-year, but exceeded the consensus estimate by 1.9% [2] - Access fees revenue decreased by 6% year-over-year to $525.7 million, missing the consensus estimate by 1.5% [3] - Other revenues increased by 16% year-over-year to $103.6 million, beating the consensus estimate by 22.9% [3] Segment Performance - The Integrated Care segment generated revenues of $389.5 million, a 3% year-over-year increase, surpassing both the Zacks Consensus Estimate and internal estimates [6] - The BetterHelp segment's revenues declined by 11% year-over-year to $239.9 million, although it beat the consensus estimate [7] Operational Metrics - Total visits decreased by 3% year-over-year to 4.4 million, falling short of the consensus estimate by 0.1% [8] - U.S. Integrated Care Members reached 102.5 million, a 12% year-over-year increase, exceeding the consensus mark by 1.2% [8] Expense and Cash Flow - Total expenses rose by 2.3% year-over-year to $750 million, exceeding internal estimates [5] - Operating cash flow improved to $15.9 million from $8.9 million year-over-year, while free cash outflow decreased to $15.7 million from $26.6 million [10] Outlook - For the second quarter, Integrated Care segment revenues are expected to grow by 0.25%-2.75% year-over-year, with an adjusted EBITDA margin forecasted between 13.25-14.75% [11] - Full-year revenues are projected to be between $2.468 billion and $2.576 billion, with a net loss expected between 90 cents and $1.40 per share [15]